Get the Stockscreener App
0.52
25.18%
-0.175
Lyra Therapeutics Inc stock is traded at $0.52, with a volume of 11,775.
It is down -25.18% in the last 24 hours and down -72.34% over the past month.
LYRA THERAPEUTICS INC
See More
Previous Close:
$0.695
Open:
$0.4501
24h Volume:
11,775
Relative Volume:
22.86
Market Cap:
$N/A
Revenue:
$398.00K
Net Income/Loss:
$-28.92M
P/E Ratio:
-0.0402
EPS:
-12.9458
Net Cash Flow:
$-28.98M
1W Performance:
-25.18%
1M Performance:
-72.34%
6M Performance:
-93.96%
1Y Performance:
-95.42%
1-Day Range:
$0.3622
$0.52
1-Week Range:
$0.3622
$0.52
52-Week Range:
$0.3622
$0.695
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Compare LYRA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.52 | 0 | 398.00K | -28.92M | -28.98M | -12.95 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Enterprise value to EBIT forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Lyra Therapeutics stock trades steadily as sinusitis implant program advances - Ad-hoc-news.de
Price to earnings forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Enterprise value to EBITDA forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Enterprise value to revenue forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Price to sales forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
LYRA stock tracks Lyra Therapeutics after recent filing context. - Ad Hoc News
Lyra Therapeutics, Inc. Actuals & Estimates (OTC:LYRA) - TradingView
Lyra Therapeutics Inc (LYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LYRA Forecast — Price Target — Prediction for 2027 - TradingView
Lyra Therapeutics Inc (LYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lyra Therapeutics Inc (LYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lyra Therapeutics Inc (LYRA) Institutional Confidence - TradingKey
Lyra Therapeutics Inc (LYRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lyra Therapeutics Inc (LYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lyra Therapeutics Inc (LYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lyra Therapeutics Inc (LYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lyra Therapeutics Inc (LYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Fulcrum shrinks headcount 85% - Fierce Biotech
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates - MSN
Lyra Therapeutics (LYRA) director surrenders 640 shares to issuer - Stock Titan
Lyra Therapeutics Inc (OTCM:LYRA) SEC filings - GuruFocus
Lyra Therapeutics Inc (OTCM:LYRA) Stock Price & 30 Year Financial Data - GuruFocus
Lyra Therapeutics Inc (LYRA) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Lyra Therapeutics Inc (OTCM:LYRA) Stock Earnings Transcripts - GuruFocus
Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - MSN
[15-12G] Lyra Therapeutics, Inc. SEC Filing - Stock Titan
6 biotechs that called it quits in Q1 - BioSpace
Lyra Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled - MSN
Total common shares outstanding of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Lyra Therapeutics (NASDAQ: LYRA) files Form 25 to delist from Nasdaq Capital Market - Stock Titan
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC - Sahm
Lyra Therapeutics to delist from Nasdaq, suspend SEC reporting By Investing.com - Investing.com India
Lyra Therapeutics (LYRA) Plans Voluntary Delisting from Nasdaq - GuruFocus
Lyra Therapeutics ends Waltham sublease, agrees to $2.1 million termination payment - Investing.com
Lyra Therapeutics Ends Major Office Sublease Agreement - TipRanks
Lyra Therapeutics (NASDAQ: LYRA) pays $2.1M to exit Waltham lease - Stock Titan
Lyra Therapeutics to delist from Nasdaq, suspend SEC reporting - Investing.com
Lyra Therapeutics, Inc. Announces Intention to Voluntarily - GlobeNewswire
After layoffs, biotech exits 2 Boston-area leases - NBC Boston
After layoffs, Lyra Therapeutics exits Watertown and Waltham leases - The Business Journals
Analyst Upgrade: Is BioRestorative Therapies Inc still a buy after recent gainsInsider Selling & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Lyra Therapeutics Streamlines Operations with Major Lease Terminations - The Globe and Mail
Lyra Therapeutics to end leases early for Watertown and Waltham facilities By Investing.com - Investing.com South Africa
Lyra Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Stock Info, and Key Disclosures (March 31, 2026) - Minichart
Lyra Therapeutics to end leases early for Watertown and Waltham facilities - Investing.com
Lyra Therapeutics (NASDAQ: LYRA) exits two office leases early - Stock Titan
Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals
Lyra Therapeutics (LYRA) CEO returns 2,000 shares to issuer - Stock Titan
Lyra Therapeutics (LYRA) officer returns 667 shares to issuer - Stock Titan
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Cap:
|
Volume (24h):